このエントリーをはてなブックマークに追加
ID 46718
本文ファイル
著者
Karino, Fumi
Nishimura, Nobuhiro
Ishihara, Noriyuki
Moriyama, Hidehiko
Miura, Kiyotaka
Hamaguchi, Shunichi
Sutani, Akihisa
Kuraki, Takashige
Ikawa, Kazuro 大学院医歯薬保健学研究科(薬) 広大研究者総覧
Morikawa, Norifumi 大学院医歯薬保健学研究科(薬) 広大研究者総覧
Naora, Kohji
Isobe, Takeshi
キーワード
piperacillin–tazobactam
Japanese late elderly patient
nephrotoxicity
nursing and healthcare associated pneumonia
NDC
医学
抄録(英)
This study aimed to clarify the efficacy, safety, and pharmacokinetics of piperacillin-tazobactam (PIPC–TAZ) in late elderly Japanese patients. This is the first antimicrobial pilot study in late elderly patients with nursing and healthcare associated pneumonia. After PIPC–TAZ administration, PIPC concentrations in plasma were measured chromatographically and the pharmacokinetic parameters were estimated. Efficacy, safety, and bacteriological evaluations were also carried out. The mean age was 85.0 years old and most of the patients were late elderly. Chest X-rays, body temperature, white blood cell count, and C reactive protein all improved significantly, and a high efficacy ratio of 90.9% was observed. Serious nephrotoxicity was observed in 4 cases (18.2%) after administration of PIPC–TAZ. Creatinine clearance (mean±S.D.) measured before PIPC–TAZ therapy was significantly lower in the nephrotoxicity group (32.5±4.4 mL/min) than in the non-nephrotoxicity group (46.1±16.7 mL/min), although the ages were not different between the 2 groups. In the pharmacokinetic parameters for PIPC, total clearance was slightly lower in the nephrotoxicity group than in the non-nephrotoxicity group. However, no significant difference was observed in plasma PIPC levels between the 2 groups. In patients with renal impairment, especially with a creatinine clearance of <40 mL/min, renal impairment was found to be an influencing factor for severe nephrotoxicity following PIPC–TAZ administration. In conclusion, the results suggest that physicians should pay close attention in order to avoid possible toxicity, and that deliberate administration planning and careful follow-up are required in late elderly patients with comprised organ dysfunction.
掲載誌名
Biological and Pharmaceutical Bulletin
37巻
12号
開始ページ
1971
終了ページ
1976
出版年月日
2014-12-01
出版者
The Pharmaceutical Society of Japan
ISSN
0918-6158
1347-5215
NCID
出版者DOI
NAID
言語
英語
NII資源タイプ
学術雑誌論文
広大資料タイプ
学術雑誌論文
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
権利情報
Copyright (c) 2014 The Pharmaceutical Society of Japan
関連情報URL
部局名
医歯薬保健学研究科